Mitral regurgitation

Mitral regurgitation (MR) refers to when the mitral valve closes incompletely during systole, causing blood to flow back from the left ventricle into the left atrium. It’s a common valvular heart disease.

MR can be primary, due to direct involvement of the valve itself or the chorda tendinae, or secondary, due to changes in the dimensions of the left ventricle, making it impossible for the anatomically normal mitral valve to close properly. It can also be either acute or chronic.

In acute MR, increased left ventricular end-diastolic volume causes backward congestion, causing pulmonary congestion or oedema.

In chronic MR, the heart compensates the increased LV end-diastolic volume by eccentric hypertrophy, dilating the chamber. However, over time, this compensatory mechanism leads to myocardial dysfunction and too large chamber, leading to heart failure.

Etiology

• Primary
  • Idiopathic degeneration of the mitral valve
  • Endocarditis
  • Rheumatic fever
• Secondary
  • Dilated cardiomyopathy
  • Coronary artery disease (ischaemia of the papillary muscles)

Clinical features

In acute MR, acute dyspnoea develops. In chronic MR, chronic heart failure develops. In case of acute MR, no murmur is typical, but in chronic MR there’s a holosystolic murmur with a “blowing” characteristic at the site of the apex. This murmur radiates to the left axilla.

Atrial fibrillation is common in chronic MR.

Diagnosis and evaluation

Echocardiography allows for assessment of the mitral valve motion during systole, and it can visualise regurgitated blood flow. Coronary angiography can be used to assess the degree of coronary artery disease.

Treatment

Surgery, either valve repair or replacement, is the definitive treatment for MR. In case of acute primary MR, urgent surgery is indicated. In case of chronic primary MR, surgery is indicated if the LVEF is decreased or the patient is symptomatic. However, if the LVEF is severely decreased (<30%), surgery is not recommended due to high mortality rate and low likelihood of improvement.

While waiting for surgery, pharmacological therapy for heart failure is required.